Serum High-Density Lipoprotein-Cholesterol Levels Modify the Association between Plasma Levels of Oxidatively Modified Low-Density Lipoprotein and Coronary Artery Disease in Men

Metabolism: Clinical and Experimental

Volumn 53, Issue 4, 2004, Pages 423-429

  Zhang, Bo ^b   Bai, Huai ^b   Liu, Rui ^b   Kumagai, Koichiro ^b   Itabe, Hiroyuki ^b   Takano, Tatsuya ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 1842427252     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.10.028     Document Type: Article

References (41)

1. Han J, Hajjar DP, Febbraio M, et al: Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem 272:21654-21659, 1997
2. Itabe H, Takeshima E, Iwasaki H, et al: A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 269:15274-15279, 1994
3. Holvoet P, Mertens A, Verhamme P, et al: Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:844-848, 2001
4. Toshima S, Hasegawa A, Kurabayashi M, et al: Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20:2243-2247, 2000
5. Dotevall A, Hulthe J, Rosengren A, et al: Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci (Lond) 101:523-531, 2001
6. Erkkila AT, Narvanen O, Lehto S, et al: Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20:204-209, 2000
7. Holvoet P, Vanhaecke J, Janssens S, et al: Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98:1487-1494, 1998
8. Holvoet P, Stassen JM, Van Cleemput J, et al: Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 18:100-107, 1998
9. Holvoet P, Van Cleemput J, Collen D, et al: Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 20:698-702, 2000
10. Itabe H, Yamamoto H, Imanaka T, et al: Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 37:45-53, 1996
11. Kugiyama K, Sugiyama S, Soejima H, et al: Increase in plasma levels of oxidized low-density lipoproteins in patients with coronary spastic angina. Atherosclerosis 154:463-467, 2001
12. Gordon DJ, Probstfield JL, Garrison RJ, et al: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8-15, 1989
13. Gordon DJ, Rifkind BM: High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 321:1311-1316, 1989
14. Tall AR: An overview of reverse cholesterol transport. Eur Heart J 19:A31-35, 1998
15. Paszty C, Maeda N, Verstuyft J, et al: Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 94:899-903, 1994
16. Rubin EM, Krauss RM, Spanler EA, et al: Inhibition of early atherosclerosis in transgenic mice by human apolipoprotein AI. Nature 353:265-266, 1991
17. Plump AS, Scott CJ, Breslow JL: Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 91:9607-9611, 1994
18. Plump AS, Erickson SK, Weng W, et al: Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production [see comments]. J Clin Invest 97:2660-2671, 1996
19. Singh K, Chander R, Kapoor NK: High density lipoprotein subclasses inhibit low density lipoprotein oxidation. Indian J Biochem Biophys 34:313-318, 1997
20. Sakai M, Miyazaki A, Hakamata H, et al: Reconstituted high density lipoprotein reduces the capacity of oxidatively modified low density lipoprotein to accumulate cholesteryl esters in mouse peritoneal macrophages. Atherosclerosis 119:191-202, 1996
21. Castelli WP: Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol 4:5a-10a, 1988
22. Saku K, Zhang B, Ohta T, et al: Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. J Am Coll Cardiol 33:436-443, 1999
23. Judkins MP: A percutaneous transfemoral technique. Radiology 89:815-821, 1967
24. Saku K, Jimi S, Sasaki N, et al: Reduced coronary vasodilation in patients with familial hypercholesterolemia following intracoronary injection of isosorbide dinitrate. Jpn Circ J 59:808-814, 1995
25. Saku K, Zhang B, Shirai K, et al: Hyperinsulinemic hypoalphalipoproteinemia as a new indicator for coronary heart disease. J Am Coll Cardiol 34:1443-1451, 1999
26. 2+, and an anion-exchange resin. Clin Chem 24:1504-1508, 1978
27. Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345-1353, 1955
28. Ikeda T, Shibuya U, Sugiuchi H, et al: Automated immunoturbidimetric analysis of six plasma apolipoproteins: correlation with radioimmunodiffusion assays. J Clin Lab Anal 5:90-95, 1991
29. Abe A, Maeda S, Makino K, et al: Enzyme-linked immunosorbent assay of lipoprotein(a) in serum and cord blood. Clin Chim Acta 177:31-40, 1988
30. Bronzert TJ, Brewer JB Jr: New micromethod for measuring cholesterol in plasma lipoprotein fractions. Clin Chem 23:2089-2098, 1977
31. SAS Institute Inc. SAS Procedures Guide, version 6 (ed 3). Cary, NC, SAS Institute, 1990
32. SAS Institute Inc. SAS/STAT User's Guide, version 6, vol 2 (ed 4). Cary, NC, SAS Institute, 1990
33. Shih DM, Gu L, Xia YR, et al: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287, 1998
34. Clinical Studies by Multivariate Analysis: Introduction to Proportional Hazards Model and Logistic Model with Application Programs of SAS. Nagoya, Japan, Nagoya Univ. Publishing House, 1990
35. Washio M, Sasazuki S, Kodama H, et al: Role of hypertension, dyslipidemia and diabetes mellitus in the development of coronary atherosclerosis in Japan. Jpn Circ J 65:731-737, 2001
36. Miwa K, Nakagawa K: Risk factors that discriminate 'high-risk' from 'low-risk' Japanese patients with coronary artery disease. Jpn Circ J 64:825-830, 2000
37. Kambara H, Imoto A, Owada C, et al: Coronary risk factors used to predict coronary artery disease by logistic regression analysis. Jpn Circ J 56:1199-1205, 1992
38. Chait A, Brazg RL, Tribble DL, et al: Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94:350-356, 1993
39. Mackness MI, Durrington PN, Mackness B: How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 11:383-388, 2000
40. Okamoto H, Yonemori F, Wakitani K, et al: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406:203-207, 2000
41. Pearson TA, Derby AA: Invited commentary: Should arteriographic case-control studies be used to identify causes of atherosclerotic coronary artery disease? Am J Epidemiol 134:123-128, 1991